| Measure | Time; % of physicians | Adjusted % change, QIIP group v. control group (95% CI)* | ||
|---|---|---|---|---|
| 12 mo before intervention or index date | 12 mo after intervention or index date | |||
| Hemoglobin A1c test: ≥ 2 in previous 12 mo | QIIP group | 41.1 | 51.4 | 4.3 (1.2 to 7.5) |
| Control group | 42.7 | 48.0 | ||
| Retinal examination: ≥ 1 in previous 24 mo | QIIP group | 72.5 | 76.6 | 2.5 (0.8 to 4.4) |
| Control group | 71.6 | 73.3 | ||
| Low-density lipoprotein cholesterol test: ≥ 1 in previous 12 mo | QIIP group | 56.9 | 64.0 | 1.3 (-2.1 to 4.6) |
| Control group | 59.5 | 64.7 | ||
| Billing for diabetes flow sheet (K030): ≥ 1 in previous yr | QIIP group | 27.6 | 42.8 | 8.8 (4.1 to 13.5) |
| Control group | 34.4 | 39.0 | ||
| Billing for preventive care of diabetes (Q040) | QIIP group | 21.7 | 39.1 | 8.9 (2.9 to 14.9) |
| Control group | 28.8 | 35.0 | ||
| Diabetes medication management for patients with type 2 diabetes > 65 yr | ||||
| Prescribed statin | QIIP group | 66.5 | 74.5 | 3.4 (0.8 to 6.0) |
| Control group | 67.6 | 71.9 | ||
| Prescribed angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker | QIIP group | 74.1 | 78.4 | 4.1 (1.8 to 6.4) |
| Control group | 76.0 | 75.0 | ||
| Prescribed orally administered hypoglycemic agent | QIIP group | 59.6 | 59.2 | 0.8 (-1.8 to 3.3) |
| Control group | 58.7 | 57.6 | ||
| Prescribed insulin | QIIP group | 17.1 | 18.5 | -0.3 (-2.3 to 1.7) |
| Control group | 15.9 | 17.9 | ||
Note: CI = confidence interval, QIIP = Quality Improvement and Innovation Partnership.
*Generalized linear regression adjusted for baseline value, sex, rurality, age and comorbidity (Johns Hopkins Adjusted Diagnosis Groups30).